Wednesday 16 September 2026

One To Watch

Adverum Biotechnologies

A clinical-stage biotech developing gene therapies as a new standard of care for highly prevalent ocular diseases.

Company Overview

Want to Update your Company's Profile?


Latest Adverum Biotechnologies News

Lilly to expand gene therapy portfolio with buy of Adverum
25 October 2025
Research shows stellar growth for gene therapies in ophthalmology
5 April 2024
Well-funded advanced therapy firm takes aim at wet AMD
6 February 2024
BRIEF—Adverum wins orphan designation for possible HAE therapy
24 August 2018
More Adverum Biotechnologies news >


Today's issue

Vivan and Ad Atomica pair tumor genotype data with AI drug design
Biotechnology
Vivan and Ad Atomica pair tumor genotype data with AI drug design
16 September 2026
Pharmaceutical
ICER releases evidence report on treatment for Parkinson’s disease
16 September 2026
Pharmaceutical
Remepy welcomes new CMO to advance hybrid drug pipeline
16 September 2026
Pharmaceutical
Sling Therapeutics announces $123M financing
16 September 2026
Pharmaceutical
Top-20 Novartis shareholder demands board shake-up after back-to-back trial failures
16 September 2026
Pharmaceutical
FDA unveils expedited IND pilot, begins accepting applications
16 September 2026
Biotechnology
Lundbeck wins Japanese approval for Vyepti
16 September 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze